What Cissus Quadrangularis Treats: Main Uses and Benefits

The traditional application of Cissus Quadrangularis, often referred to as 'Hadjod,' generally relates to supporting the structural health of the body. It is commonly used in situations involving physical damage or systemic fragility of the skeletal and connective tissues. Within traditional systems, the supplement's uses are primarily focused on supporting bone health and integrity.

Supportive Benefit Clusters

This botanical is applied in contexts requiring supportive assistance for conditions involving acute bone injury after a fracture, for managing joint discomfort and symptoms related to the stability of tendons and ligaments, and in situations of structural weakness like age-related bone loss. The primary benefit Cissus is used for is to provide support during episodes of heightened discomfort related to structural strain. This may assist with managing symptom clusters that interfere with daily functioning, such as localized pain, swelling, and reduced mobility. It is often used to help with these symptoms in clinical settings that involve acute or unstable symptom patterns and to contribute to the supportive management of skeletal integrity.

---

Quick Fact: Support for Musculoskeletal Pain Cissus is relevant for easing symptoms of physical discomfort linked to structural issues in the joints and bones, and may assist with maintaining a sense of stability when symptoms are more noticeable.

Who Can and Cannot Use Cissus Quadrangularis?

The eligibility profile for Cissus Quadrangularis, a botanical supplement, is defined by regulatory caution and the established data from government-registered clinical trials.

---

Eligibility Status by Population

Population Group	Regulatory Status	Constraint Basis
Adults (18–65 years)	Allowed	Established profile in clinical studies.
Children/Adolescents	Use Not Established	Excluded from primary studies (under 18 years).
Older Adults	Use Not Established	Excluded from primary studies (over 65 years).
Pregnant/Lactating Females	Not Recommended	Insufficient reliable safety data.
Known Hypersensitivity	Contraindicated	Universal pharmacological prohibition.
Diabetes Mellitus	Conditional Use	Risk of interference with blood glucose control.
Scheduled Surgery	Conditional Restriction	Must be discontinued two weeks prior to procedure.

---

The primary population for whom use is supported by data is the general adult cohort (18 to 65 years). Regulatory caution dictates that the botanical is not recommended for pregnant or breastfeeding women due to a lack of reliable safety information. Use is strictly contraindicated in any patient with a known allergy to the supplement. Furthermore, use requires conditional monitoring for patients with Diabetes Mellitus and must be discontinued before scheduled surgeries.

Interactions with Other Medicines and Products

The interaction profile of Cissus Quadrangularis (Veldt Grape) is primarily determined by its potential to affect blood glucose levels, which may lead to significant pharmacodynamic interactions with co-administered substances.

Documented Interaction Profile

The central concern is the risk of an additive effect that could result in hypoglycemia (low blood sugar).

Substance Category	Interaction Classification	Practical Implication
Antidiabetes Drugs (e.g., insulin, glimepiride, metformin)	Moderate Pharmacodynamic Interaction	Requires caution; may necessitate adjustment of antidiabetes medication to prevent hypoglycemia.
Herbs/Supplements (with blood sugar-lowering effects)	Additive Risk Caution	Increases the overall risk of hypoglycemia when combined with substances like bitter melon or chromium.

---

Procedural Constraints

Due to its potential influence on blood glucose control, Cissus Quadrangularis carries a specific procedural requirement stated in regulatory guidance:

• Scheduled Surgery: Use of the supplement must be discontinued at least two weeks prior to any scheduled surgical procedure. This measure is intended to prevent interference with blood sugar regulation during and after the operation.

No official regulatory documentation specifies pharmacokinetic interactions involving CYP enzymes or drug transporters (e.g., P-gp) for this product.

The activity of Cissus quadrangularis is defined by a dual action: targeted anabolic stimulation of bone tissue and broad anti-inflammatory modulation via enzymatic inhibition. The resulting physiological consequence is shaped by the concurrent intervention across several key biological pathways.

Anabolic Shift in Bone Remodeling

The mechanism initiates a change in the ratio of bone formation to resorption by acting as a modulator of cellular signaling. It activates the Wnt/beta-catenin pathway to promote the differentiation and proliferation of bone-forming cells (osteoblasts) and simultaneously limits the activity of bone-resorbing cells (osteoclasts). This shift is supported by the antagonism of the Glucocorticoid Receptor, which limits stress-hormone signaling that mediates bone catabolism. This collective action enhances new bone matrix synthesis and the deposition of bone matrix components.

Eicosanoid and Catabolic Pathway Inhibition

Cissus modulates the physiological response by serving as a non-selective inhibitor of the key inflammatory enzymes Cyclooxygenase (COX) and Lipoxygenase (LOX). This interference with the arachidonic acid cascade reduces the local production of mediators like prostaglandins. Furthermore, the compounds inhibit the p38 MAPK pathway in joint tissue, which reduces chondrocyte degradation. This leads to a decreased concentration of localized inflammatory mediators and contributes to the modulation of connective tissue function.

Synergy: Signal and Substrate Delivery

The mechanism is completed by the unique synergistic relationship between the signaling phytochemicals and the high concentration of natural Calcium, Phosphorus, and Vitamin C. The phytochemicals provide the molecular signal for osteoblast activity, while the minerals and cofactors provide the essential physical substrates required to execute the rapid biomineralization of the newly forming tissue.

How to Use Cissus Quadrangularis: Administration Guidelines

Cissus quadrangularis is classified as a botanical supplement, and its usage protocols are based on traditional pharmacopoeias and established practices. The instructions below outline the standard procedures for administration and dosing.

Administration Scope

Category	General Instructions
Route of Administration	The primary route is Oral (Capsule, Tablet, Powder, or Juice). Traditional use also includes Topical application as a paste for external support.
Dosing Schedule (Adults)	The typical range for the standardized extract is 300 mg to 1,500 mg per day. For the traditional dried powder, the range is often 3 g to 6 g daily.
Frequency	The product is generally administered in divided doses Twice Daily (BID) to ensure continuous systemic presence.
Timing in Relation to Meals	Traditional recommendations advise ingestion after meals (post-food).
Age-Group Rules	The use in the pediatric population (children over 5) often requires a reduced dose.

Contextual Use Instructions

Preparation and Intake Conditions: The powdered form is often mixed with a liquid vehicle before ingestion. Traditional protocols frequently specify using warm milk or water to accompany the dose.

Course Duration: Administration is typically structured for a short course of 6 to 12 weeks for acute support, or continued for 90 days or more for long-term structural maintenance.

These guidelines standardize the consumption of Cissus quadrangularis by defining the required form, dose ranges, and timing, without addressing its mechanism of action or therapeutic effects.

Cissus Quadrangularis: Recent Clinical Evidence

Evidence for Structural Bone Weakness

Clinical trials have explored the supplement's use in relation to biochemical markers of bone structure and stability, particularly in cohorts such as postmenopausal women with low bone density (osteopenia). Researchers focused on monitoring Bone Turnover Markers (BTMs) over defined time intervals. In one 24-week Randomized Controlled Trial, trials reported measurements of these markers, but Bone Mineral Density (BMD) measurements did not show a measurable change over the study period. Systematic reviews report that this evidence is currently classified as having very low certainty by reviewers.

Evidence for Bone Fracture Healing

This area summarizes research that has explored whether the supplement was associated with the context of acute bone injury. Research examined outcomes related to physical discomfort and the time recorded for bone fragments to join. The evidence base consists primarily of short-term clinical studies. Studies monitored how symptoms evolved in the observed populations, and some trials described patterns related to changes in physical discomfort and localized swelling when compared to control groups. However, certainty for the evidence on fracture healing is described as low by reviewers, due to modest sample sizes and variations in formulations used.

What Research Still Needs to Clarify

Reviewers assess the overall certainty of the available clinical evidence for the supplement's use in bone and joint health as low or very low. This is connected to several limitations, including modest sample sizes, limited follow-up durations, and evidence quality that varies across studies. Key questions that research still needs to clarify include confirming the clinical relevance of measured shifts in specific bone biomarkers and gathering long-term data to characterize the maintenance of any observed biochemical patterns.

Key Studies & References

1. The effect of Cissus quadrangularis on joint pain-a placebo-controlled clinical trial.

Common questions about Cissus Quadrangularis (FAQ)

Q: Is Cissus Quadrangularis a type of steroid or hormone?

A: Official information describes Cissus Quadrangularis as containing natural anabolic steroidal compounds (phytochemicals) that are believed to influence bone metabolism. However, the supplement is classified as a botanical product derived from a plant, and not a single pharmaceutical drug or hormone.

---

Q: Does Cissus Quadrangularis affect blood sugar levels?

A: Yes, regulatory and official safety summaries indicate that Cissus Quadrangularis has the potential to lower blood sugar levels. This metabolic effect is a primary reason why conditional use constraints are noted for individuals taking antidiabetes medications.

---

Q: Can Cissus Quadrangularis be taken with blood-thinning medications?

A: Official interaction documentation primarily focuses on the risk of blood sugar-lowering effects. Specific, reliable regulatory data on potential drug interactions between Cissus Quadrangularis and common blood-thinning (anticoagulant/antiplatelet) medications are not specifically outlined in the available safety summaries.

---

Q: Has Cissus Quadrangularis been studied for its effect on weight management?

A: Yes, scientific reviews and clinical trials registered on government databases have examined the use of Cissus Quadrangularis extracts, sometimes in combination with other ingredients, in the context of weight management and parameters related to obesity.

---

Q: Are there any studies on Cissus Quadrangularis and athletic performance?

A: Research has predominantly focused on the supplement's traditional use for bone healing and its described mechanism of anabolic stimulation of bone tissue. The anabolic properties described in the mechanism of action are an area that is often examined in research.

---

Q: Why do bodybuilders often use Cissus Quadrangularis?

A: Traditional and preclinical information cited in regulatory documents suggest the botanical contains compounds described as having anabolic properties and supporting connective tissue health. This described mechanism is often referenced in discussions regarding the supplement's traditional use for supporting physical structure.

---

Q: Is Cissus Quadrangularis safe to use for long periods?

A: Official safety profiles are predominantly based on data from short-term use in controlled clinical studies, typically lasting up to 10 weeks. Reliable safety data extending beyond this duration is not available in government-registered regulatory summaries.

---

Q: What is the longest time people have studied using Cissus Quadrangularis?

A: Systematic reviews of human clinical trials have analyzed studies with administration periods ranging from 4 weeks up to a maximum of approximately 24 weeks (6 months). The safety profile that has been established is generally based on these shorter study durations.

---

Q: What kind of scientific evidence is there for Cissus Quadrangularis?

A: Clinical evidence themes include research examining the botanical’s effects on markers related to bone maintenance, aspects of bone fracture healing, and physical discomfort related to joint health. Reviewers generally classify the certainty of this available clinical evidence as low or very low.

---

Q: Is the evidence for Cissus Quadrangularis mostly from animal studies or human trials?

A: Evidence summaries include findings from both human randomized controlled trials and various preclinical studies (animal or lab-based). The preclinical research often provides the foundational support for the proposed biological mechanisms.

---

Q: Is Cissus Quadrangularis approved by the FDA for any specific condition?

A: In the United States, Cissus Quadrangularis is marketed as a dietary or food supplement. It does not hold FDA approval for use as a pharmaceutical drug to treat, cure, or prevent any specific disease or medical condition.

---

Q: Can Cissus Quadrangularis affect my sleep?

A: Adverse reaction data cited in official summaries document occasional reports of effects related to the Nervous System, specifically including either insomnia (difficulty sleeping) or general sleepiness.

---

Q: Is it normal to feel a tingling sensation after taking Cissus Quadrangularis?

A: The most commonly documented adverse effects in regulatory summaries are related to gastrointestinal issues, headache, and changes in sleep patterns. A tingling sensation is not specifically included among the most commonly documented adverse reactions in official safety summaries.

---

Q: What are the general safety classifications for Cissus Quadrangularis extracts?

A: Cissus Quadrangularis is officially classified as a Herbal/Botanical Supplement. Its regulatory pathway differs from a pharmaceutical drug, and its safety is assessed primarily through preclinical studies and ongoing safety monitoring.

---

Q: Can Cissus Quadrangularis interact with any mental health medications?

A: Official interaction documentation focuses on blood glucose-lowering drugs. Specific drug interaction data with common mental health medications are not generally documented in official safety summaries.

---

Q: What does 'research evidence theme' mean regarding Cissus Quadrangularis?

A: This term refers to the main topics or categories that researchers investigate when studying the supplement. For Cissus Quadrangularis, the established themes include structural bone weakness, fracture healing, and the behavior of bone turnover markers.

---

Q: Can Cissus Quadrangularis be used by teenagers?

A: Use of the supplement is categorized as 'Use Not Established' for the pediatric population (under 18 years) in official safety documents. This classification is due to the lack of sufficient primary clinical study data available for this specific age group.

---

Q: What does the evidence say about Cissus Quadrangularis for tendon health?

A: The general purpose of the supplement is described as supporting bones, joints, and connective tissue maintenance in authoritative sources. While core clinical studies often focus on bone structure and fractures, the overall purpose is described for supporting connective tissue function.

---

Q: Has Cissus Quadrangularis been studied for its effect on cholesterol?

A: Yes, clinical studies cited in official reviews have investigated the effect of Cissus Quadrangularis on lipid profiles, which includes measurements of total cholesterol, LDL-cholesterol, and triglycerides. These studies investigated its influence on lipids alongside other metabolic parameters.

---

Q: Does Cissus Quadrangularis need to be cycled (taken for a period and then stopped)?

A: Official documents do not provide administration instructions on cycling. However, the established safety profile is limited to short-term use, and long-term data for continuous use are not reliably established in regulatory summaries.

Official Storage and Disposal Requirements

The storage and handling requirements for Cissus Quadrangularis are governed by maintaining the stability and integrity of the material, as defined in regulatory documentation.

Storage Category	Requirement
Temperature	Store in a cool place; avoid excessive heat.
Protection	Keep protected from direct sunlight and moisture.
Packaging	Store in a tightly sealed, light-resistant container.
Child Safety	Must be stored out of the reach of children.
Disposal	Disposal should follow local regulations and government guidelines for non-hazardous materials, typically permitting discard in household trash by mixing with an undesirable substance. Do not flush the product unless specifically instructed by an official disposal program.